Madison Asset Management LLC Acquires Shares of 2,107,675 Armata Pharmaceuticals, Inc. $ARMP

Madison Asset Management LLC acquired a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) in the 1st quarter, HoldingsChannel reports. The fund acquired 2,107,675 shares of the company’s stock, valued at approximately $21,583,000. Madison Asset Management LLC owned approximately 0.06% of Armata Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in Armata Pharmaceuticals during the fourth quarter worth about $108,000. Millennium Management LLC acquired a new position in Armata Pharmaceuticals in the fourth quarter valued at approximately $164,000. OMERS ADMINISTRATION Corp purchased a new stake in Armata Pharmaceuticals in the 4th quarter worth approximately $177,000. SeaCrest Wealth Management LLC boosted its position in Armata Pharmaceuticals by 17.3% in the 4th quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after purchasing an additional 6,034 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Armata Pharmaceuticals during the 4th quarter worth approximately $284,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Armata Pharmaceuticals to a “hold” rating in a report on Monday, May 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Armata Pharmaceuticals Stock Up 12.2%

ARMP stock opened at $5.06 on Tuesday. The company’s 50-day simple moving average is $6.86 and its 200-day simple moving average is $8.34. Armata Pharmaceuticals, Inc. has a 52-week low of $2.32 and a 52-week high of $16.34. The firm has a market cap of $185.75 million, a P/E ratio of -0.65 and a beta of 1.26.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($3.16) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($2.78). The company had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.74 million. On average, analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.88 earnings per share for the current fiscal year.

Armata Pharmaceuticals Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.